Astellas Pharma Sues Toyo Pharmar and Aska Pharmaceutical for Patent Infringement.Tokyo, Japan, Nov 30, 2005 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Astellas Pharma Astellas Pharma Inc. (アステラス製薬株式会社 announced on November 29 that it has filed a lawsuit against Toyo Pharmar and Aska Pharmaceutical for infringement on Astellas' patents on tamsulosin hydrochloride tamsulosin hydrochloride Bazetham (UK), Flomax, Flomaxtra (UK), Stronazon (UK), Tabphyn (UK) Pharmacologic class: Alpha-adrenergic blocker Therapeutic class: Anti-adrenergic Pregnancy risk category B in the Tokyo District Court Tokyo District Court (東京地方裁判所; Tōkyō Chihō Saibansho) is a district court in Kasumigaseki, Chiyoda, Tokyo, Japan. See also
Astellas Pharma claims that it holds a formulation patent of tamsulosin hydrochloride that expires in March 2006. Tamsulosin hydrochloride is a selective alpha-1 blocker indicated for the treatment of urinary disturbance. Currently, Astellas Pharma is marketing a sustained-release formation of tamsulosin hydrochloride under the trade name of Harnal 0.1mg/0.2mg Capsules Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion